PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
PROPEL abstract — abi/pred + olaparib. Different outcomes between this trial and the MAGNITUDE trial on men withOUT HRR mutatated cancers. therefore, probably will combine parp inhibitor w/abiraterone/pred in men who are otherwise candidates for PARP inhibitors but not yet in men who are not otherwise candidates for PARP inhibitor therapy.